TransMedics Group (TMDX) Competitors $114.97 -4.88 (-4.07%) Closing price 04:00 PM EasternExtended Trading$115.50 +0.53 (+0.47%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TMDX vs. SNN, SOLV, PEN, STVN, GKOS, BLCO, IRTC, SLNO, NVST, and LIVNShould you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), iRhythm Technologies (IRTC), Soleno Therapeutics (SLNO), Envista (NVST), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry. TransMedics Group vs. Its Competitors Smith & Nephew SNATS Solventum Penumbra Stevanato Group Glaukos Bausch + Lomb iRhythm Technologies Soleno Therapeutics Envista LivaNova Smith & Nephew SNATS (NYSE:SNN) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment. Which has higher valuation & earnings, SNN or TMDX? Smith & Nephew SNATS has higher revenue and earnings than TransMedics Group. Smith & Nephew SNATS is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmith & Nephew SNATS$5.81B2.80$412M$2.1617.22TransMedics Group$441.54M8.88$35.46M$1.9359.57 Which has more risk & volatility, SNN or TMDX? Smith & Nephew SNATS has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Do institutionals & insiders believe in SNN or TMDX? 25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 7.0% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is SNN or TMDX more profitable? TransMedics Group has a net margin of 13.49% compared to Smith & Nephew SNATS's net margin of 0.00%. TransMedics Group's return on equity of 28.02% beat Smith & Nephew SNATS's return on equity.Company Net Margins Return on Equity Return on Assets Smith & Nephew SNATSN/A N/A N/A TransMedics Group 13.49%28.02%8.64% Does the media favor SNN or TMDX? In the previous week, Smith & Nephew SNATS had 7 more articles in the media than TransMedics Group. MarketBeat recorded 18 mentions for Smith & Nephew SNATS and 11 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 1.34 beat Smith & Nephew SNATS's score of 1.02 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer SNN or TMDX? Smith & Nephew SNATS currently has a consensus price target of $36.00, indicating a potential downside of 3.21%. TransMedics Group has a consensus price target of $123.00, indicating a potential upside of 6.98%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than Smith & Nephew SNATS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew SNATS 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00TransMedics Group 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78 SummaryTransMedics Group beats Smith & Nephew SNATS on 13 of the 17 factors compared between the two stocks. Get TransMedics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TMDX vs. The Competition Export to ExcelMetricTransMedics GroupMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.09B$7.12B$5.82B$9.75BDividend YieldN/A1.28%4.40%4.08%P/E Ratio59.5726.9130.1425.84Price / Sales8.8875.42469.15120.64Price / Cash72.8422.3525.7828.79Price / Book16.884.859.425.99Net Income$35.46M$176.42M$3.27B$265.29M7 Day Performance-8.50%-0.15%2.05%2.53%1 Month Performance6.34%-2.91%3.58%0.92%1 Year Performance-34.55%8.70%30.09%18.70% TransMedics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TMDXTransMedics Group2.7532 of 5 stars$114.97-4.1%$123.00+7.0%-31.8%$4.09B$441.54M59.57210Positive NewsAnalyst ForecastSNNSmith & Nephew SNATS3.1602 of 5 stars$36.45+0.7%$36.00-1.2%+21.5%$15.97B$5.81B16.8817,349News CoveragePositive NewsAnalyst DowngradeSOLVSolventum1.6707 of 5 stars$71.390.0%$85.75+20.1%+19.6%$12.40B$8.25B33.1022,000Positive NewsAnalyst DowngradePENPenumbra4.7437 of 5 stars$253.68+0.3%$300.47+18.4%+26.0%$9.89B$1.28B67.474,500Insider TradeSTVNStevanato GroupN/A€22.57-0.2%N/A+21.1%€6.84B€1.19B41.805,521GKOSGlaukos4.715 of 5 stars$90.80+1.0%$127.42+40.3%-29.1%$5.21B$432.95M-55.03780Analyst RevisionBLCOBausch + Lomb1.6203 of 5 stars$14.56+0.0%$15.56+6.9%-8.3%$5.16B$4.79B-18.6713,500IRTCiRhythm Technologies1.3085 of 5 stars$156.40-2.6%$157.30+0.6%+141.6%$5.03B$591.84M-53.452,000Insider TradeSLNOSoleno Therapeutics4.6202 of 5 stars$70.56-1.5%$114.30+62.0%+51.5%$3.75BN/A-17.0630News CoverageNVSTEnvista3.7075 of 5 stars$20.65+0.1%$20.92+1.3%+15.9%$3.44B$2.51B64.6712,300LIVNLivaNova1.6401 of 5 stars$53.42-0.6%$59.29+11.0%+20.0%$2.92B$1.25B-13.732,900News CoveragePositive News Related Companies and Tools Related Companies Smith & Nephew SNATS Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives Bausch + Lomb Alternatives iRhythm Technologies Alternatives Soleno Therapeutics Alternatives Envista Alternatives LivaNova Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TMDX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access